Klebsiella pneumoniae bacteremia mortality: a systematic review and meta-analysis
- PMID: 37153146
- PMCID: PMC10159367
- DOI: 10.3389/fcimb.2023.1157010
Klebsiella pneumoniae bacteremia mortality: a systematic review and meta-analysis
Abstract
Objective: To analyze the mortality rate of patients with Klebsiella pneumoniae bacteremia (KPB) and the impact of extended spectrum beta-lactamase (ESBL) producing or carbapenem-resistance (CR) KP on the mortality rate among patients with bacteremia.
Methods: EMbase, Web of Science, PubMed, and The Cochrane Library were searched up to September 18th, 2022. Two reviewers independently extracted data and evaluated risk of bias of included studies by ROBINS-I tool. A meta-regression analysis was conducted using a mixed-effects model to explore possible sources of heterogeneity. A random-effects model was used for pooled analysis in case of significant heterogeneity (I2>50%). Otherwise, the fixed-effects model was performed.
Results: A total of 157 studies (37,915 enrolled patients) were included in the meta-analysis. The pooled death proportions of KPB were 17% (95% CI=0.14-0.20) at 7-day, 24% (95% CI=0.21-0.28) at 14-day, 29% (95% CI=0.26-0.31) at 30-day, 34% (95% CI=0.26-0.42) at 90-day, and 29% (95% CI=0.26-0.33) in hospital, respectively. Heterogeneity was found from the intensive care unit (ICU), hospital-acquired (HA), CRKP, and ESBL-KP in the meta-regression analysis. More than 50% of ICU, HA, CRKP, and ESBL-KP were associated with a significant higher 30-day mortality rates. The pooled mortality odds ratios (ORs) of CRKP vs. non-CRKP were 3.22 (95% CI 1.18-8.76) at 7-day, 5.66 (95% CI 4.31-7.42) at 14-day, 3.87 (95% CI 3.01-3.49) at 28- or 30-day, and 4.05 (95% CI 3.38-4.85) in hospital, respectively.
Conclusions: This meta-analysis indicated that patients with KPB in ICU, HA-KPB, CRKP, and ESBL-KP bacteremia were associated with a higher mortality rate. The high mortality rate caused by CRKP bacteremia has increased over time, challenging the public health.
Keywords: Klebsiella pneumoniae; bacteremia; carbapenem-resistant; meta-analysis; mortality.
Copyright © 2023 Li, Huang, Rao, Yu, Long, Li and Zhang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Multidrug-resistant Klebsiella pneumoniae coinfection with multiple microbes: a retrospective study on its risk factors and clinical outcomes.mSystems. 2025 Jul 10:e0175724. doi: 10.1128/msystems.01757-24. Online ahead of print. mSystems. 2025. PMID: 40638073
-
Carbapenem Resistance, Initial Antibiotic Therapy, and Mortality in Klebsiella pneumoniae Bacteremia: A Systematic Review and Meta-Analysis.Infect Control Hosp Epidemiol. 2017 Nov;38(11):1319-1328. doi: 10.1017/ice.2017.197. Epub 2017 Sep 27. Infect Control Hosp Epidemiol. 2017. PMID: 28950924
-
Monotherapy vs combination therapy in patients with Klebsiella pneumoniae bloodstream infection: A systematic review and meta-analysis.J Infect Chemother. 2024 May;30(5):372-378. doi: 10.1016/j.jiac.2024.02.007. Epub 2024 Feb 17. J Infect Chemother. 2024. PMID: 38369125
-
A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant Klebsiella pneumoniae versus Escherichia coli.Front Cell Infect Microbiol. 2025 Jun 17;15:1600746. doi: 10.3389/fcimb.2025.1600746. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40599648 Free PMC article.
-
Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia.J Infect Public Health. 2025 Sep;18(9):102836. doi: 10.1016/j.jiph.2025.102836. Epub 2025 May 22. J Infect Public Health. 2025. PMID: 40460690
Cited by
-
Risk Factors for Multidrug Resistance in Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae: A Nomogram.Infect Drug Resist. 2024 Nov 3;17:4833-4841. doi: 10.2147/IDR.S479374. eCollection 2024. Infect Drug Resist. 2024. PMID: 39498412 Free PMC article.
-
General Overview of Klebsiella pneumonia: Epidemiology and the Role of Siderophores in Its Pathogenicity.Biology (Basel). 2024 Jan 27;13(2):78. doi: 10.3390/biology13020078. Biology (Basel). 2024. PMID: 38392297 Free PMC article. Review.
-
Antibiotic resistance in hospital wastewater in West Africa: a systematic review and meta-analysis.BMC Public Health. 2025 Apr 11;25(1):1364. doi: 10.1186/s12889-025-22513-w. BMC Public Health. 2025. PMID: 40217451 Free PMC article.
-
Clinical characteristics, risk factors and prognosis of Klebsiella pneumoniae infection in patients with different states of immune function: a retrospective study.Front Cell Infect Microbiol. 2025 May 30;15:1539554. doi: 10.3389/fcimb.2025.1539554. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40521023 Free PMC article.
-
New insights and perspectives on the virulence of hypervirulent Klebsiella pneumoniae.Folia Microbiol (Praha). 2025 Jun;70(3):517-533. doi: 10.1007/s12223-025-01261-9. Epub 2025 Apr 8. Folia Microbiol (Praha). 2025. PMID: 40198504 Review.
References
-
- Balkan I. I., Alkan M., Aygun G., Kuskucu M., Ankarali H., Karagoz A., et al. . (2021). Colistin resistance increases 28-day mortality in bloodstream infections due to carbapenem-resistant klebsiella pneumoniae. Eur. J. Clin. Microbiol. Infect. Dis. 40 (10), 2161–2170. doi: 10.1007/s10096-020-04124-y - DOI - PubMed
-
- Castanheira M., Deshpande L. M., Mendes R. E., Canton R., Sader H. S., Jones R. N. (2019). Variations in the occurrence of resistance phenotypes and carbapenemase genes among isolates in 20 years of the SENTRY antimicrobial surveillance program. Open Forum Infect. Dis. 6 (Suppl 1), S23–S33. doi: 10.1093/ofid/ofy347 - DOI - PMC - PubMed
-
- CDC (2022). Available at: https://www.cdc.gov/drugresistance/national-estimates.html.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources